Year: 2023

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the publication today of its financial results for the third quarter ended Sept. 30, 2023 and provided a business update. THIRD QUARTER 2023 FINANCIAL SUMMARYR&D expenses for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022. Marketing, general and administrative expenses for the three months ended Sept. 30, 2023 amounted to $0.97 million compared to $0.96 million for the three months ended Sept. 30, 2022. Total...

Consolidated Uranium Announces Filing and Mailing of the Management Information Circular in Connection with its Special Meeting of Shareholders to Approve the Merger with IsoEnergy

Written by Customer Service on October 31, 2023. Posted in Mergers And Acquisitions.

• Your vote is important no matter how many votes you hold.• The Board of Directors of CUR recommends that Shareholders vote IN FAVOUR of the Arrangement Resolution.• Shareholders who have questions or need assistance with voting their shares should contact Consolidated Uranium’s proxy solicitation agent and shareholder communications advisor Laurel Hill Advisory Group by telephone at 1-877-452-7184 or by email at assistance@laurelhill.com. TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) — Consolidated Uranium Inc. (“CUR” or “Consolidated Uranium”) (TSXV: CUR) (OTCQX: CURUF) is pleased to announce its notice of special meeting of shareholders (the “Meeting”) and management information circular (the “Circular”) are now available on CUR’s website at https://consolidateduranium.com/investors/special-meeting/ as well as under CUR’s...

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. “I’m very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness”, said Sujal Patel, CEO of Nautilus. “Continuing to increase the scale and robustness of the platform remains a key area of focus as we ready the platform for launch next year. With an increasing focus on proteomics by the scientific community, moves by major life science companies to expand their proteomics-related offerings, and massive international investments in the study of proteins, it is clear to me that a strong foundation has been laid for the ‘proteomics era’ of...

Hubbell Reports Third Quarter 2023 Results

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

Shelton, CT, Oct. 31, 2023 (GLOBE NEWSWIRE) — Exhibit 99.1 HUBBELL REPORTS THIRD QUARTER 2023 RESULTSQ3 diluted EPS from continuing operations of $3.70; adjusted diluted EPS from continuing operations of $3.95 Q3 net sales +5% (organic +4%, acquisitions +1%) Operating margin expansion of 460 bps; adjusted operating margin expansion of 440 bps Raise FY23 diluted EPS from continuing operations to $14.00-$14.25; adjusted diluted EPS of $15.00-$15.25SHELTON, CT. (October 31, 2023) – Hubbell Incorporated (NYSE: HUBB) today reported operating results for the third quarter ended September 30, 2023. “Hubbell delivered strong earnings growth for shareholders in the third quarter,” said Gerben Bakker, Chairman, President and CEO. “We continued to drive significant margin expansion in the quarter through effective execution on price,...

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported third quarter 2023 financial results and recent portfolio execution. “We continue to advance all aspects of our business, including strong revenue growth with ARCALYST and clinical trial execution with KPL-404, and we have...

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million Orders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to range of $635-$645 millionWALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023. Tony J. Hunt, Chief Executive Officer of Repligen said, “While the broader challenges that have dominated our industry over the last twelve months continued in the third quarter, we saw positive signs of recovery. Our order book strengthened by mid-quarter, delivering an overall book-to-bill of 1.07 by quarter end....

Christina Lake Cannabis Reports Third Quarter 2023 Results

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) is pleased to report its financial results for the third quarter ended August 31, 2023 (“Q3’23”). All amounts are expressed in Canadian dollars unless otherwise noted. Q3’23 HighlightsRevenue up 30% to $8.9M over nine-month period end Q3’22; Distillate volumes sold increased by 85% compared to the nine-month period ending Q3’22; Gross profit of $4.0M or 45.2% before fair value adjustments for the nine-month period; Decreased G&A expenses by $137k or 4% from prior year period“Through a steadfast commitment to meeting our customers’ ever-expanding demands and consistently delivering high quality products, CLC has continued to maintain...

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

Written by Customer Service on October 31, 2023. Posted in Earnings Releases And Operating Results.

Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800 for Third Quarter 2023 Remain Committed and Continue to Pursue Idiopathic Hypersomnia Indication; Next Step to Meet with FDA Informed by Review of Full Data Set Expanded and Diversified Pipeline with Acquisition of Zynerba Pharmaceuticals; Zygel™ in Pivotal Phase 3 Trial for Fragile X syndrome Repurchased ~1.4 Million Shares of Common Stock for $50 Million in Third Quarter 2023; Board of Directors Authorized New $200 Million Share Repurchase Program Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (“Harmony” or...

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Written by Customer Service on October 31, 2023. Posted in Public Companies.

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences: J.P. Morgan Equity Opportunities ForumMonday, November 6 – Tuesday, November 7, 2023 in Miami, FL UBS Biopharma Conference 2023Wednesday, November 8, 2023 at 11:00 a.m. ET. in Miami, FL A live and achieved webcast of the Company’s fireside chat at the UBS Biopharma Conference 2023 can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download...

Solid Power, Inc. Announces Timing of Third Quarter 2023 Earnings Release Date and Conference Call

Written by Customer Service on October 31, 2023. Posted in Public Companies.

LOUISVILLE, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) — Solid Power, Inc. (Nasdaq: SLDP), a developer of solid-state battery technology, today announced that it will release its third quarter 2023 results after market close on Tuesday, November 7, 2023, to be followed by a conference call at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested investors and other parties can listen to a webcast of the live conference call through Solid Power’s Investor Relations website at ir.solidpowerbattery.com. The conference call can also be accessed live over the phone by dialing +1-844-826-3035 (domestic) or +1-412-317-5195 (international). A recording of the conference call will be available approximately three hours after the completion of the call at ir.solidpowerbattery.com or by dialing +1-844-512-2921 (domestic), or +1-412-317-6671...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals